Physician profile
Angelo Mallozzi
NPI 1689768558
$1,609.75
in general payments reported to CMS, 2019-2025
18 companies · $746 in 2025
The $746 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $31.27 · 2024: $832 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $225.98 | 2024-2025 | |
| Esperion Therapeutics, INC. | $222.12 | 2024-2025 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $167.62 | 2024-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $162.71 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $112.74 | 2024 | |
| Novartis Pharmaceuticals Corporation | $98.84 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.88 | 2024-2025 | |
| Exact Sciences Corporation | $95.51 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $89.87 | 2024-2025 | Rexulti |
| Ardelyx, INC. | $86.57 | 2024-2025 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.67 | 2023-2024 | Caplyta |
| Lilly USA, LLC | $55.42 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $31.15 | 2025 | Shingrix |
| Lundbeck LLC | $27.53 | 2025 | Rexulti |
| Astellas Pharma US INC | $22.38 | 2025 | Veozah |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.39 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.26 | 2025 | Xifaxan |
| Dexcom, INC. | $17.11 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Mallozzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.